Investigational drug · Phase 2
Sevasemten
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Becker Muscular Dystrophy, Duchenne Muscular Dystrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
6
Any phase or sponsor naming "Sevasemten"
First trial start
2022
Oct 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sevasemten", any sponsor or status.
Conditions studied
As listed on its trial records.
- Becker Muscular Dystrophy
- Duchenne Muscular Dystrophy
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Sevasemten" as an intervention, largest first.
- Open-Label Extension of EDG-5506 in Participants With Becker Muscular DystrophyEnrolling by invitation
Edgewise Therapeutics, Inc.Industry
NCT06066580 · 260 participants (planned) · Start Nov 2, 2023 · Primary completion Feb 2031
Drug: Sevasemten · For: Becker Muscular Dystrophy
Sites: Little Rock, Arkansas; La Jolla, California; Los Angeles, California · 48 sites in all
- Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)Pivotal-lookingCompleted
Edgewise Therapeutics, Inc.Industry
NCT05291091 · 244 participants · Start Nov 10, 2022 · Primary completion Sep 7, 2026
Drug: Sevasemten 10 mg; Sevasemten 5 mg and 2 more · For: Becker Muscular Dystrophy
Sites: Little Rock, Arkansas; La Jolla, California; Los Angeles, California · 51 sites in all
- A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)Active, not recruiting
Edgewise Therapeutics, Inc.Industry
NCT05540860 · 76 participants · Start Oct 24, 2022 · Primary completion Jan 2027
Drug: Sevasemten Dose 1; Sevasemten Dose 2 and 4 more · For: Duchenne Muscular Dystrophy
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 14 sites in all
- Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyActive, not recruiting
Edgewise Therapeutics, Inc.Industry
NCT06100887 · 43 participants · Start Mar 22, 2024 · Primary completion Mar 2027
Drug: Sevasemten Dose 1; Sevasemten Dose 2 and 2 more · For: Duchenne Muscular Dystrophy
Sites: Los Angeles, California; Sacramento, California; Gainesville, Florida · 7 sites in all
Edgewise Therapeutics, Inc.Industry
NCT06916897 · 42 participants · Start Jan 8, 2025 · Primary completion Feb 22, 2025
Drug: sevasemten; Verapamil · For: Healthy Subjects
Sites: Tempe, Arizona; Lincoln, Nebraska
Edgewise Therapeutics, Inc.Industry
NCT05160415 · 12 participants · Start Dec 28, 2021 · Primary completion Mar 1, 2024
Drug: Sevasemten · For: Becker Muscular Dystrophy
Sites: Atlanta, Georgia
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1 Evaluation of the Pharmacokinetics of Sevasemten (EDG-5506) for Potential Food Effect and Drug-Drug Interaction With a CYP3A4 Moderate Inhibitor.
Madden M, Dreghici RD, Silverman JA · Clin Transl Sci 2026
- Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.
Madden M, Evanchik M, Lane J, et al. · J Clin Pharmacol 2026
- Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study.
Phan H, Barthel B, Madden M, et al. · EBioMedicine 2026
- A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy.
Donovan J, Silverman JA, Barthel B, et al. · Muscle Nerve 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.